Please provide your email address to receive an email when new articles are posted on . Machine learning algorithms developed to predict improvement in patients with mild nonproliferative diabetic ...

Please provide your email address to receive an email when new articles are posted on . Four-year outcomes of the DRCR Retina Network Protocol W study showed that preventive aflibercept vs. sham ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Prophylactic ...

BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

To report estimates of the prevalence of diabetic retinopathy (DR) and maculopathy grades for a large cohort of patients managed by the UK hospital eye service (HES). Between 2007 and 2010, 307 538 ...

To investigate the relationship between subfoveal choroidal thickness, severity of diabetic retinopathy (DR), and the presence of diabetic macular oedema (DMO) using enhanced depth imaging spectral ...

AAO: American Academy of Ophthalmology; CDA: Canadian Diabetes Association; DM: Diabetes mellitus; ISPAD: International Society for Pediatric and Adolescent Diabetes; NHMRC: National Health and ...

COPENHAGEN, Denmark, June 24, 2025 /PRNewswire/ -- Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment ...

CHICAGO -- Diabetic patients without retinopathy achieved 20/20 vision after cataract surgery as often as nondiabetic patients did, a retrospective analysis of a large community-based cohort showed.

Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease ...